stock decline

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant application. Stock plummeted 50.4% following December rejection. Investor deadline April 21, 2026.

D-Wave ($QBTS) fell 44% in 2026 despite strong bookings exceeding 2025 totals and $30M in major deals. Analysts see 132% upside, but 237x sales valuation remains extreme.

Pomerantz Law Firm investigates $OMF following multi-state lawsuit alleging deceptive lending practices. Stock tumbles 5.38% on fraud allegations.

Boston Scientific faces class action lawsuit alleging material misstatements about electrophysiology growth. Stock fell 17.6% after disclosing slower market growth and competitive pressures.

Pomerantz LLP filed securities fraud class action against Nektar Therapeutics, alleging false statements about clinical trial enrollment procedures led to trial failure and stock decline.

Pomerantz LLP sues Inovio Pharmaceuticals for alleged securities fraud over FDA approval misstatements. Stock fell 3.1% and 24.45% following manufacturing delays and accelerated approval rejection.

NHTSA escalates investigation into Tesla's Full Self-Driving system across 3.2M vehicles, threatening autonomy growth narrative as stock slides 25% from recent highs.

ODDITY Tech ($ODD) faces securities fraud lawsuit after 49% stock plunge over alleged non-disclosure of advertising algorithm changes that spiked customer acquisition costs.

$ALIT shareholders have until May 15, 2026 to join securities fraud lawsuit over alleged misstatements. Stock fell 18.3% and 38.2% after guidance misses in August 2025 and February 2026.

Lenz Therapeutics stock plummeted 11.2% after Q4 earnings miss, larger-than-expected losses, and disappointing VIZZ prescription uptake despite strong pipeline projections.

Ridgetech shares fell 23.74% to $2.73 in premarket trading Tuesday amid broader market weakness and concerns about its 2026 growth strategy execution.

Portnoy Law Firm sues BellRing Brands for allegedly inflating organic sales growth through customer inventory stockpiling, citing 52% stock decline following revelations.

Estée Lauder shares fell 7.72% to $79.29 after announcing preliminary merger discussions with Spanish luxury giant Puig Brands. No final decision made; deal pending regulatory approval.

Securities class action filed against $COTY for failing to disclose weakness in beauty and fragrance segments. Stock fell 22% following disappointing Q2 results and guidance withdrawal.

C3.ai stock falls 36% YTD after former CEO's resignation amid intensifying competition in enterprise AI market.

Snowflake faces securities fraud suit after 18% stock drop on corrective disclosures regarding consumption patterns and $10B revenue target claims.

Apollo Global Management faces securities fraud lawsuit over undisclosed Epstein business dealings. Stock fell 5% as investors explore class action eligibility through May 1, 2026.

Lululemon stock down nearly 50% amid CEO departure, weak North American sales, and sluggish 2026 growth guidance. International gains offer hope.

Sarissa Capital deploys $5.79M in beaten-down biotech Biohaven despite 70% stock decline, betting on upcoming late-stage trial data and obesity candidate.

ODDITY Tech faces securities fraud lawsuit after 49% stock plunge; company failed to disclose advertising partner algorithm changes that increased customer acquisition costs.